India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
China to issue ‘K-visa’ to attract foreign talent in IT sector China is set to issue ‘K-visa’ to attract the world’s skilled workforce in the information technology sector. China has come up with such a plan targeting technicians who are looking for an alternative path after the US recently increased the fee for H-1B visas. The initiative is seen as a strong step for Beijing in the geopolitical competition between the US and China. Although China has a sufficient number of local engineers, it is said that it is trying to provide a comfortable environment for foreign investment and talent to address the growing trade tensions and the economic slowdown. Earlier, China had also taken initiatives such as granting visa exemptions to citizens of European countries, Japan and South Korea to promote foreign investment and tourism. Although the ‘K-visa’ was announced last August, it is said that it will be implemented from this week. The new visa is targeted at people with degrees in infor...